Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 3NIH 3NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 50Vincristine 49Doxorubicin 44Prednisone 42Rituximab 32Radiotherapy 27Etoposide 27Methotrexate 24Filgrastim 24Cytarabine 23Dexamethasone 15Granulocyte Colony-Stimulating Factor 13Bleomycin 13Vinblastine 12Peripheral Blood Stem Cell Transplantation 12Leucovorin 11Gene Expression Profiling 10Bortezomib 10Immunohistochemistry 9Procarbazine 8Polymerase Chain Reaction 8Gemcitabine 8Melphalan 7Amplified Fragment Length Polymorphism Analysis 7VAP-cyclo protocol 6Mercaptopurine 6Ifosfamide 6Dacarbazine 6Carmustine 6Microarray Analysis 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lymphoma × denileukin diftitox × Clear all
NCT00003615 2023-06-15

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Eastern Cooperative Oncology Group

Phase 2 Completed
77 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡